Watch the Latest OMNARIS TV Commercial
Check back soon.
Check back soon.
Use this interactive checklist to create your own personalized Doctor Discussion Guide.
OMNARIS® (ciclesonide) Nasal Spray is for the treatment of nasal allergy symptoms associated with seasonal allergies in adults and children 6 years of age and older, and with year-round allergies in adults and adolescents 12 and older. It is for use in the nose only. OMNARIS is used 1 time each day, 2 sprays per nostril.
Do not spray OMNARIS Nasal Spray in your eyes or directly onto your nasal septum (the wall inside your nose between your two nostrils).
OMNARIS Nasal Spray may cause serious side effects, including:
The most common side effects that may occur with OMNARIS Nasal Spray are headache, nosebleed, sore throat and ear pain.
Tell your doctor if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of OMNARIS Nasal Spray.
For more information, please see the OMNARIS Full Prescribing Information and the OMNARIS Patient Information. You may also call 1-888-394-7377.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call
1-800-FDA-1088.
OMNARIS® (ciclesonide) Nasal Spray is available by prescription. Ask your healthcare professional if OMNARIS Nasal Spray is right for you.
The health information contained on this website is provided for educational purposes only and is not intended to replace discussions with a healthcare professional. This site is intended for U.S. residents 18 years of age and older. The product discussed on this site may have different product labeling in different countries. All decisions regarding patient care must be made with a healthcare professional, considering the unique characteristics of the patient.
OMNARIS is the registered trademark of Takeda GmbH, used under license. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Dainippon Sumitomo Pharma Co. Ltd., Sunovion Logo is a registered trademark of Dainippon Sumitomo Pharma Co. Ltd.
© 2013 Sunovion Pharmaceuticals Inc. All rights reserved. 01/13 OMNV070-12.